Uptake of medicines for type 2 diabetes

We're reporting on the uptake of two new type 2 diabetes medicines funded in 2021.

June 2022 will be the final update

As interest in this information has waned, we will no longer update this information monthly.

People can still request the data via Official Information Act 

Data will also be available in the Ministry of Health's Pharmaceutical Data Web Tool(external link) once 2021 and 2022 are added. 


Empagliflozin (with and without metformin) has been funded since 1 February 2021 and dulaglutide has been funded since 1 September 2021. They are funded for people with high-risk type 2 diabetes who meet certain criteria.

This was the first time we specifically name Māori and Pacific ethnicities within the funding criteria.  This was to proactively promote equity of access to this medicine. 

As part of the decision to fund this medicine, we said we would actively monitor and report on uptake. 

We update this information monthly. 

Empagliflozin (with & without metformin) and dulaglutide

Total number of people who have a Special Authority approved as at 12 June 2022: 66,355

Special Authority criteria

% of applications per criteria

Māori or Pacific ethnicity


Pre-existing cardiovascular disease


5-year cardiovascular disease risk


High lifetime cardiovascular risk (childhood or young adult)


Diabetic kidney disease



Sum of percentage of each criteria will be greater than 100% as applicants may have ticked more than one criteria. 

The criteria for Māori or Pacific ethnicity is prioritised. If an applicant has ticked the Māori or Pacific ethnicity criteria, they do not need to tick another criteria. This means that the total number of applications will underrepresent those with cardiovascular and renal risk criteria.

People with a previous Special Authority approval for empagliflozin may have changed to dulaglutide, with a different Special Authority approval. This means that there may be some double-counting of approval numbers and the true number of individual people with an approval for one of the diabetes medicines may be slightly lower than the total numbers shared above.